全球大健康領導品牌安麗（Amway）公布截至 2025 年 12 月 31 日全球業績報告，全年營收達 73 億美元。根據美國《直銷新聞》（Direct Selling News）基於 2025 年營收的評比，安麗已連續 14 年蟬聯全球 ...
我們正邁入一個全新的工作模式 — AI 已具備推理、分析與解決問題的能力，並正在重新定義企業運作方式與知識型工作的樣貌。這項轉變如同工業革命與網際網路的出現，將在未來數十年間 ...
Microsoft’s latest Work Trend Index highlights the rise of “Frontier Firms,” where AI agents are becoming part of everyday workflows and reshaping how organizations structure work, productivity, and ...
Amway’s enduring success is rooted in its ability to provide accessible solutions to modern challenges. President and CEO Michael Nelson emphasizes that the company offers a low-risk path to business ...
Amway’s global momentum in healthspan innovation helped drive $7.3 billion in 2025 sales, while Taiwan strengthened its role as a regional powerhouse with seven consecutive years of growth. Through ...
創新的藥物與疫苗不僅是科學成就，更是改變個人健康與社會韌性的生命線。透過預防、治療與治癒疾病，它們讓人們能夠活得更長久、更健康，並幫助各國建立更強健、更永續的醫療體系。
身為全球製藥領導者，羅氏（Roche）深耕台灣多年，是台灣醫療體系堅定的戰略夥伴。面對「健康台灣」願景，我們深信透過產官學緊密協作，將全球頂尖科學與台灣卓越的醫療實力結合，定能 ...
台灣輝瑞大藥廠創新藥品榮獲二項新創品質大獎肯定，分別在 2025 年「SNQ國家品質標章暨國家生技醫療品質獎」及「國家新創獎」評選中再傳捷報，獲得的三項產品橫跨腫瘤治療與預防醫學領域 ...
Pfizer Taiwan Recognized with Dual Honors from the “SNQ / National Biotechnology and Medical Care Quality Award” and “National Innovation Award” Pfizer Taiwan has been recognized with two major ...
As a global leader in pharmaceuticals and in-vitro diagnostics, Roche has cultivated a deep, enduring presence in Taiwan for decades. We consistently position ourselves not merely as a supplier of ...
Innovative medicines and vaccines are more than scientific achievements — they are lifelines that transform the health of individuals and the resilience of societies. By preventing, treating, and ...
心血管疾病仍是台灣最重要的公衛挑戰之一，其中動脈粥狀硬化心血管疾病（ASCVD）這種因動脈內斑塊堆積所引起的疾病，更占了相當高比例的發病與死亡案例。 「如果連台灣第二大死因、也是全球首要死因的疾病，都無法驅使我們採取行動，那就真的有問題了，」諾華亞太中東非洲區總裁 Judith Love ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results